



Antibody Drug Conjugates

ADCs



Introduction to ADC

Antibody Drug Conjugates (ADCs) represent a transformative approach to cancer treatment, they are targeted medicines that deliver chemotherapy agents (Small Molecule payloads) directly to cancer cells via a chemical linker attached to a monoclonal antibody (mAbs).


The chemical Linker in the ADC binds the MAB to the cytotoxin and is designed to ensure the complex molecule is stable until it reaches the Target Cancer Cell



ADC combine the targeted specificity of antibodies with the potent cytotoxicity of small molecule drug minimizing the impact on normal cells and enhancing therapeutic efficacy.





At Masco Group, we are an ideal partner to support our clients in ADC manufacturing, backed by years of experience in delivering projects for small and large molecules production processes.



We offer integrated project delivery solutions for the life sciences industry, focusing on the supply and incorporation of specialised technologies for rapid deployment of prefabricated PODs and modular facility solutions.

Containment Integration into Engineered Solutions

API Reactors and Small Production Units




Isolation and Purification

Monoclonal Antibody Manufacturing



Lyophilization technologies



At Masco Group, we are committed to supporting our clients in tackling these challenges by developing cutting-edge technology and research to refine the development processes.



Our focus is on driving our clients' 360-degree CAPEX progress through a dynamic combination of engineering, design, consulting, technologies and servicing for ADC manufacturing.

Below, you'll find a process flow diagram for antibody manufacturing that details the key steps in the process and where the Masco Group can partner with you.

